Search

Philip S Tsao

from Los Altos, CA
Age ~58
Get Report
Also known as:
Philip M Tsao, Philip S Tsar, Phil S Tsao, Phillip S Tsao, Ping Yao Tsao, Pingyao C Tsao, Margaret Tsao, Phil Taso, Margaret Kerney
Phone and address:
702 Meadow Ln, Los Altos, CA 94022
(650) 949-1443
Related to:
Li ChiangCatherine K Forsthoffer, 57Daniel F Kerney, 60Margaret A KerneyMeilin TsaoLichiang Tsao, 94Sherman M Tsao, 92Jodi K Sheeran, 59Ping Y Tsao, 92Noah L TsaoGregory B Kerney, 35Carol K Hunt, 54Margaret K Tsao, 61
Connected to:
Alex Tsao, 62Allison Tsao, 29Andrea Tsao, 32Charles C Tsao, 77Chijen J Tsao, 65Coco L Tsao, 36Gloria M Tsao, 59Jim Tsao, 63Ken K Tsao, 69Kevin Tsao, 35

Philip Tsao Phones & Addresses

  • 702 Meadow Ln, Los Altos, CA 94022 (650) 949-1443
  • Palo Alto, CA
  • 6309 Paso Los Cerritos, San Jose, CA 95120 (408) 927-6379
  • Philadelphia, PA
  • Broomall, PA
  • Menlo Park, CA
  • Cupertino, CA
  • Santa Clara, CA

Work

Company: Employment development department (edd) Aug 2009 Position: Senior programmer analyst consultant

Education

School / High School: DePaul University- Chicago, IL 1985 Specialities: Computer Science

Resumes

Resumes

Philip Tsao Photo 1

Philip Tsao Sacr

View page
Work:
EMPLOYMENT DEVELOPMENT DEPARTMENT (EDD)

Aug 2009 to 2000
Senior Programmer Analyst Consultant
EDWARD JONES
St. Louis, MO
Apr 2008 to Dec 2008
Senior Programmer Analyst Consultant
DEPARTMENT OF CHILD SUPPORT SERVICES
San Francisco, CA
Jun 2004 to Feb 2008
Senior Programmer Analyst Consultant
COMDISCO
Rosemont, IL
Oct 1995 to Oct 2003
Database Administrator / Senior Programmer Analyst
MIDWEST SECURITIES AND TRUST COMPANY
Chicago, IL
Apr 1993 to Oct 1995
Senior Programmer Analyst
UNITED AIRLINES INC
Elk Grove Village, IL
Dec 1987 to Mar 1993
Programmer Analyst
Education:
DePaul University
Chicago, IL
1985
Computer Science
Northeastern Illinois University
Chicago, IL
1982
B.S. in Information Science

Publications

Us Patents

Nicotine Receptor Agonists In Stem Cell And Progenitor Cell Recruitment

View page
US Patent:
8163780, Apr 24, 2012
Filed:
Nov 16, 2010
Appl. No.:
12/947575
Inventors:
John Cooke - Palo Alto CA, US
Frances Lauri Johnson - Portola Valley CA, US
Anjali Pathak - Campbell CA, US
James Jang - San Bruno CA, US
Philip Tsao - San Jose CA, US
Christopher Heeschen - Menlo Park CA, US
Assignee:
The Board of Trustees of the Leland Stanford Jr. University - Palo Alto CA
International Classification:
A61K 31/44
A61K 31/445
A61K 31/40
US Classification:
514343, 514326, 514315
Abstract:
The present invention features methods for recruitment of bone marrow-derived stem cells (e. g. , endothelial cell precursors, hematopoietic stem cells) by administration of nicotine or other nicotine receptor agonist. The methods of the invention can be used in, for example, treatment of conditions amenable to treatment by recruitment of bone marrow-derived stem cells (e. g. , neutropenia).

Nicotine Receptor Agonists In Stem Cell And Progenitor Cell Recruitment

View page
US Patent:
20050038079, Feb 17, 2005
Filed:
Feb 13, 2004
Appl. No.:
10/779090
Inventors:
John Cooke - Palo Alto CA, US
Frances Johnson - Portola Valley CA, US
Anjali Pathak - Campbell CA, US
James Jang - San Bruno CA, US
Philip Tsao - San Jose CA, US
Christopher Heeschen - Menlo Park CA, US
International Classification:
A61K031/4439
US Classification:
514343000
Abstract:
The present invention features methods for recruitment of bone marrow-derived stem cells (e.g., endothelial cell precursors, hematopoietic stem cells) by administration of nicotine or other nicotine receptor agonist. The methods of the invention can be used in, for example, treatment of conditions amenable to treatment by recruitment of bone marrow-derived stem cells (e.g., neutropenia).

Use Of Deltapkc Peptides For Modulation Of Reactive Oxygen Species

View page
US Patent:
20050267030, Dec 1, 2005
Filed:
Apr 29, 2005
Appl. No.:
11/119098
Inventors:
Philip Tsao - Los Altos CA, US
International Classification:
A61K038/18
A61K038/48
US Classification:
514012000, 424094500
Abstract:
Methods for modulating the level of reactive oxygen species (ROS) in a cell or tissue by administering compounds that modulate the activity of δPKC are described. In one embodiment, the level of ROS is decreased by administering a peptide effective to inhibit the activity of δPKC. In another embodiment, the level of ROS is increased by administering a peptide having activity to agonize the activity of δPKC. Also described are methods to treat or inhibit development of conditions preceded by or exacerbated by an increased level of ROS, such as arteriosclerosis and inflammatory diseases.

Methods And Compositions For Diagnosis And Monitoring Of Atherosclerotic Cardiovascular Disease

View page
US Patent:
20070099239, May 3, 2007
Filed:
Jun 23, 2006
Appl. No.:
11/473826
Inventors:
Raymond Tabibiazar - Stanford CA, US
Philip Tsao - Los Altos CA, US
Thomas Quertermous - Stanford CA, US
Brit Turnbull - Stanford CA, US
Richard Olshen - Stanford CA, US
Evangelos Hytopoulos - San Mateo CA, US
International Classification:
G01N 33/53
G06F 19/00
US Classification:
435007100, 702019000
Abstract:
The present invention identifies circulating proteins that are differentially expressed in atherosclerosis. Circulating levels of these proteins, particularly as a panel of proteins, can discriminate patients with acute myocardial infarction from those with stable exertional angina and from those with no history of atherosclerotic cardiovascular disease. Such levels can also predict cardiovascular events, determine the effectiveness of therapy, stage disease, and the like. For example, these markers are useful as surrogate biomarkers of clinical events needed for development of vascular specific pharmaceutical agents.

Atherosclerosis Genes And Related Reagents And Methods Of Use Thereof

View page
US Patent:
20070253901, Nov 1, 2007
Filed:
Apr 27, 2006
Appl. No.:
11/412437
Inventors:
David Deng - Mountain View CA, US
Anya Tsalenko - Chicago IL, US
Amir Ben-Dor - Bellevue WA, US
Zohar Yakhini - Ramat Hasharon, IL
Thomas Quertermous - Stanford CA, US
Euan Ashley - Menlo Park CA, US
Eugene Yang - Danville CA, US
Raymond Tabibiazar - Menlo Park CA, US
Philip Tsao - Los Altos CA, US
International Classification:
A61K 51/00
A61K 49/10
C07K 16/46
C07K 14/54
US Classification:
424001690, 424009340, 530351000, 530391100
Abstract:
The invention provides genes (DEA genes) that are differentially expressed in atherosclerotic lesions and polypeptides encoded by these genes. The invention provides compositions comprising a targeting agent conjugated to a functional moiety, wherein the targeting agent selectively binds to a polypeptide encoded by one a DEA gene. The functional moiety can be an imaging agent, therapeutic agent, etc. The invention further provides methods for providing diagnostic or prognostic information related to atherosclerosis involving detecting expression or activity of an expression product of one or more of the DEA genes. The invention further provides therapeutic methods comprising administering to a subject a composition comprising a targeting agent conjugated to a functional moiety that binds selectively binds to a polypeptide encoded by a DEA gene.

Pde3B Variants

View page
US Patent:
20210285050, Sep 16, 2021
Filed:
Jul 3, 2019
Appl. No.:
17/258084
Inventors:
- Washington DC, US
Scott M. Damrauer - Philadelphia PA, US
Christopher J. O'Donnell - Boston MA, US
Philip S. Tsao - Palo Alto CA, US
Sekar Kathiresan - Boston MA, US
Daniel J. Rader - Philadelphia PA, US
Peter W.F. Wilson - Decatur GA, US
Themistocles L. Assimes - Palo Alto CA, US
International Classification:
C12Q 1/6883
A61K 31/4709
C12N 9/22
C12N 15/11
A61K 31/7088
A61K 38/46
C12N 15/113
Abstract:
Disclosed are chimeric antigen receptor (CAR) polypeptides comprising a T cell receptor (TCR) antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Disclosed are methods of making a CART cell comprising obtaining a cell from a subject diagnosed with T cell lymphoma; determining the sequence of the TCR on the cell; and transducing a T cell with a vector comprising a nucleic acid sequence that encodes a CAR polypeptide, wherein the CAR polypeptide comprises a TCR antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the TCR antigen binding domain is specific to a subsequence of the sequence of the TCR on the cell identified in the step of determining the sequence of the TCR

Processes For Genetic And Clinical Data Evaluation And Classification Of Complex Human Traits

View page
US Patent:
20210158894, May 27, 2021
Filed:
Jan 9, 2019
Appl. No.:
16/961120
Inventors:
- Stanford CA, US
- Washington DC, US
Michael P. Snyder - Stanford CA, US
Cuiping Pan - Palo Alto CA, US
Philip S. Tsao - Palo Alto CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
U.S. Government represented by the Department of Veterans Affairs - Washington DC
International Classification:
G16B 20/20
G16B 40/20
G06F 17/18
Abstract:
Processes to identify a subset of trait-related genes and classify individuals are described. Generally, systems generate classification models which are used to identify the subset of trait-related genes and classify individuals. The classification models are also used in various applications, including developing research tools, performing diagnostics, and treating individuals.

Methods, Devices, And Compositions For Treating Vascular Aneurysms

View page
US Patent:
20210059843, Mar 4, 2021
Filed:
Sep 22, 2020
Appl. No.:
17/028048
Inventors:
- Palo Alto CA, US
Isabel Schellinger - Leipzig, DE
Joshua Spin - San Jose CA, US
Philip Tsao - Los Altos CA, US
International Classification:
A61F 2/82
A61B 17/00
A61F 2/90
Abstract:
Methods, compositions, and devices for treating a vascular aneurysm, including an abdominal aortic aneurysm, are disclosed. In particular, the various embodiments relate to a method of treating an abdominal aortic aneurysm by increasing the mechanical stiffness of an aortic segment adjacent to the abdominal aortic aneurysm in a subject. The mechanical stiffness of the adjacent aortic segment may be increased, for example, by applying a surgical adhesive or intravascular stent. Such treatment reduces stress on the aortic wall and limits further growth of the abdominal aortic aneurysm.
Control profile
Philip S Tsao from Los Altos, CA, age ~58 Get Report